ADHD (attention deficit hyperactivity disorder) diagnostics co gets $8.5m backing
This article was originally published in Clinica
BioBehavioural Diagnostics (BioBDx) is to kickstart commercialisation of its McLean Motion and Attention Test for Attention Deficit Hyperactivity Disorder (MMAT/ADHD) system, using the $8.5m raised in a series A financing. The round was co-led by Sevin Rosen Funds and Tullis-Dickerson. The FDA-approved MMAT/ADHD system is designed to measure, in a noninvasive, objective and precise manner, the severity of the core symptoms of ADHD, says Cambridge, Massachusetts-based BioBDx. These symptoms include inattention, hyperactivity and impulsivity. The system is expected to be launched in the US in 2008.